Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03461718
Recruitment Status : Completed
First Posted : March 12, 2018
Last Update Posted : July 8, 2020
Sponsor:
Information provided by (Responsible Party):
Jerome Edelson, Brooke Army Medical Center

Brief Summary:
We will be investigating the use of ketamine in sedation for endoscopic procedures, specifically outpatient endoscopy including esophagoduodenoscopy (EGD) and colonoscopy. Participants will be randomized to one of two arms including conventional moderate sedation with midazolam and fentanyl or the ketamine arm. They will then undergo the planned procedure. Physicians preforming the procedure will be surveyed following the procedure and patients will be surveyed twice, once after meeting criteria for discharge on day of the procedure and a second time 48 hours following the procedure.

Condition or disease Intervention/treatment Phase
Administration and Dosage of Ketamine Endoscopic Sedation Drug: Ketamine Drug: Midazolam injection Drug: Fentanyl Phase 2

Detailed Description:
In this study, the investigators plan to conduct a single blinded randomized controlled trial in the Gastroenterology Service to demonstrate the efficacy of ketamine and its utility in moderate sedation. Patients presenting to the endoscopy lab for esophagogastroduodenoscopy (EGD) and/or colonoscopy who meet inclusion criteria will be approached, and if amenable, will be consented and enrolled. Patients will be randomized to receive either a ketamine loading dose and then subsequent doses IV ketamine and midazolam 1mg IV prior to administration of ketamine or standard fentanyl/midazolam moderate sedation during their procedure. Participants will then undergo the planned procedure. The primary outcome will be patient satisfaction, which will be measured using the validated "Patient Satisfaction with Sedation" instrument (PSSI). A number of secondary outcomes will include the following: (1) provider satisfaction (measured using and the "Clinician Satisfaction with Sedation" instrument (CSSI), (2) the time from sedation administration to procedure start (when the scope is inserted), (3) the time from sedation to recovery (defined as the time from the end of the procedure until the patient meets discharge criteria from the recovery area), (4) time to cecum (for colonoscopy) total doses of medications given (midazolam, fentanyl, and ketamine), (5) overall time of the procedure, (6) adverse events, (7) changes in vital signs, (8) and the need for additional medications, in particular reversal agents.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Ketamine as a Sedation Adjunct for Endoscopic Procedures
Actual Study Start Date : March 5, 2018
Actual Primary Completion Date : October 1, 2019
Actual Study Completion Date : October 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy
Drug Information available for: Ketamine

Arm Intervention/treatment
Experimental: Ketamine
Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
Drug: Ketamine
Experimental arm for sedation.

Drug: Midazolam injection
Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction

Active Comparator: Control
This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.
Drug: Midazolam injection
Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction

Drug: Fentanyl
Part of standard sedation regimen




Primary Outcome Measures :
  1. Provider satisfaction [ Time Frame: Measured within 15 minutes post proceudre ]
    Measured with CSSI score. This consists of a questionnaire administered to the provider following the procedure with questions detailing different aspects of the procedure. Answers will be summed and the scores are normalized to a scale of 0-100 (high scores denote higher satisfaction).


Secondary Outcome Measures :
  1. Sedation time [ Time Frame: During the procedure ]
    Time from sedation administration until procedure start, will be measured in minutes

  2. Time to cecum (for colonoscopy) [ Time Frame: During the procedure ]
    Time required for endoscopist to reach the cecum, will be measured in minutes

  3. Total dose of medications given [ Time Frame: During the procedure ]
    All doses of medications will be summed and reported.

  4. Overall procedure time [ Time Frame: During the procedure ]
    The time from procedure start to procedure completion will be measured in minutes

  5. Adverse events [ Time Frame: During the procedure ]
    Are detailed in the protocol. We will be recording the presence or absence of adverse events.

  6. Changes in vital signs [ Time Frame: During the procedure ]
    As defined in the protocol. We will be recording all vital signs for later analysis.

  7. Need for additional medications, ie reversal agents [ Time Frame: During the procedure ]
    Will be measured as yes or no, specific dose and medication will be recorded for analysis.

  8. Patient Satisfaction [ Time Frame: After patient reaches criteria for discharge as listed above, a survey will be preformed. It will also be preformed 48 hours post procedure with the patients being called. Two surveys will end patient participation in the study. ]
    Measured with PSSI score. This consists of a questionnaire administered to the provider following the procedure with questions detailing different aspects of the procedure. Answers will be summed and the scores are normalized to a scale of 0-100 (high scores denote higher satisfaction). Criteria for discharge are at least 30 minutes elapsed since the last dose of sedative medication was administered, presence of protective reflexes (swallow and gag), stable vital signs, patient passes trial of ambulation (if was ambulating prior to procedure, a responsible adult is present to drive patient home and remain with the patient the length of two half-lives of the medications administered for sedation, and there are no staff concerns about safety. After the patient meets discharge criteria, a survey will be preformed. It will also be repeated once at the 48 hour post-procedure time. Conclusion of the two surveys concludes patient participation in the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients age 18 to 65 years who present to the GI clinic for an EGD or colonoscopy

Exclusion Criteria:

  • Poor vital sign stability
  • Hypoxia: O2 < 92%,
  • Hypotension, hypertension, heart rate and respiratory rates greater than 20% above or below normal as dictated by normal ranges in SAMMC protocol
  • Any allergy to ketamine, fentanyl, or midazolam
  • Patient is pregnant or refuses pregnancy test, in women of child-bearing potential.*
  • American Society of Anesthesiologists (ASA) score>3
  • Presence of a history of psychosis, hallucinations, and/or a psychotic disorder
  • History of increased intracranial pressure/ hypertensive hydrocephalus within the last 3 months
  • Active pulmonary infection or disease.
  • History of airway instability, tracheal surgery, or tracheal stenosis.

    • * Not applicable if patient is a female over 50 years old or has had a hysterectomy and/or oophorectomy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03461718


Locations
Layout table for location information
United States, Texas
Brooke Army Medical Center
Fort Sam Houston, Texas, United States, 78234
Sponsors and Collaborators
Brooke Army Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Jerome C Edelson, MD BAMC
Study Chair: John G Gancayco, MD BAMC
Study Director: Cyrus V Edelson, MD BAMC
Layout table for additonal information
Responsible Party: Jerome Edelson, Physician, Brooke Army Medical Center
ClinicalTrials.gov Identifier: NCT03461718    
Other Study ID Numbers: C.2017.175
First Posted: March 12, 2018    Key Record Dates
Last Update Posted: July 8, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Fentanyl
Midazolam
Ketamine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics, Opioid
Narcotics
Adjuvants, Anesthesia
Hypnotics and Sedatives
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents